OptiNose (OPTN) News Today $9.17 0.00 (0.00%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$9.17 0.00 (0.00%) As of 03/25/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25 at 11:17 PM | morningstar.comHC Wainwright Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)March 24 at 2:30 AM | americanbankingnews.comOptiNose (NASDAQ:OPTN) Earns Neutral Rating from Piper SandlerMarch 24 at 1:37 AM | americanbankingnews.comOptiNose (NASDAQ:OPTN) Cut to "Hold" at Piper SandlerPiper Sandler downgraded shares of OptiNose from a "strong-buy" rating to a "hold" rating in a research report on Thursday.March 23 at 8:01 AM | marketbeat.comOptiNose (NASDAQ:OPTN) Cut to Hold at Lake Street CapitalMarch 23 at 3:33 AM | americanbankingnews.comPiper Sandler Reiterates Neutral Rating for OptiNose (NASDAQ:OPTN)Piper Sandler reissued a "neutral" rating and issued a $9.00 price objective (down from $15.00) on shares of OptiNose in a research note on Friday.March 22, 2025 | marketbeat.comOptiNose (NASDAQ:OPTN) Given Neutral Rating at HC WainwrightHC Wainwright reissued a "neutral" rating and issued a $9.00 target price (down previously from $18.00) on shares of OptiNose in a report on Friday.March 22, 2025 | marketbeat.comOptinose downgraded to Neutral from Buy at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNMarch 21, 2025 | businesswire.comOptinose downgraded to Neutral from Overweight at Piper SandlerMarch 21, 2025 | markets.businessinsider.comOptinose downgraded to Hold from Buy at Lake StreetMarch 21, 2025 | markets.businessinsider.comLake Street Downgrades OptiNose (OPTN)March 21, 2025 | msn.comWhy OptiNose Inc. (OPTN) Surged On Thursday?March 21, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of ShareholdersMarch 21, 2025 | globenewswire.comOptiNose (NASDAQ:OPTN) Downgraded by Lake Street Capital to "Hold"Lake Street Capital cut OptiNose from a "buy" rating to a "hold" rating in a report on Thursday.March 21, 2025 | marketbeat.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | gurufocus.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | prnewswire.comOPTN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Optinose, Inc. Is Fair to ShareholdersMarch 20, 2025 | tmcnet.comOptiNose climbs after take-private deal with Paratek PharmaMarch 20, 2025 | msn.comOptinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes FlightMarch 20, 2025 | msn.comShareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public ShareholdersMarch 20, 2025 | businesswire.comOptinose Cancels Fourth Quarter and Full Year 2024 Earnings CallMarch 19, 2025 | globenewswire.comParatek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)March 19, 2025 | globenewswire.comOptiNose (NASDAQ:OPTN) shareholders have endured a 90% loss from investing in the stock five years agoMarch 13, 2025 | finance.yahoo.comOptinose to Announce Q4 and Full-Year 2024 Financial Results on March 20, 2025March 13, 2025 | msn.comOptiNose (OPTN) Projected to Post Quarterly Earnings on ThursdayOptiNose (NASDAQ:OPTN) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comOptinose Announces Reporting Date for Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | markets.businessinsider.comOptiNose, Inc. (NASDAQ:OPTN) CEO Sells $33,729.04 in StockOptiNose, Inc. (NASDAQ:OPTN - Get Free Report) CEO Ramy A. Mahmoud sold 6,376 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the sale, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.March 5, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) CEO Ramy A. Mahmoud Sells 6,376 SharesMarch 5, 2025 | insidertrades.comOptiNose trading resumesMarch 4, 2025 | markets.businessinsider.comShort Interest in OptiNose, Inc. (NASDAQ:OPTN) Grows By 16.2%OptiNose, Inc. (NASDAQ:OPTN - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 247,800 shares, an increase of 16.2% from the January 15th total of 213,300 shares. Based on an average daily trading volume, of 65,200 shares, the short-interest ratio is currently 3.8 days. Approximately 3.1% of the company's shares are short sold.February 17, 2025 | marketbeat.comOptiNose, Inc. (NASDAQ:OPTN) Short Interest UpdateOptiNose, Inc. (NASDAQ:OPTN - Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 304,600 shares, a drop of 90.5% from the December 31st total of 3,190,000 shares. Based on an average daily volume of 55,300 shares, the days-to-cover ratio is currently 5.5 days. Currently, 3.8% of the company's stock are sold short.January 28, 2025 | marketbeat.comOptinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCEJanuary 18, 2025 | msn.comOptinose, Inc.: Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionJanuary 16, 2025 | finanznachrichten.deOptinose price target adjusted for stock split at Lake StreetJanuary 16, 2025 | markets.businessinsider.comLake Street Capital Has Lowered Expectations for OptiNose (NASDAQ:OPTN) Stock PriceLake Street Capital cut their target price on OptiNose from $45.00 to $17.00 and set a "buy" rating on the stock in a research report on Thursday.January 16, 2025 | marketbeat.comLake Street Remains a Buy on Optinose (OPTN)January 16, 2025 | markets.businessinsider.comOptinose Reports Q4 XHANCE Net Product Revenue; Sees Continued Growth In Year AheadJanuary 15, 2025 | markets.businessinsider.comOptinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 MillionJanuary 15, 2025 | globenewswire.comHC Wainwright Forecasts OptiNose FY2029 EarningsOptiNose, Inc. (NASDAQ:OPTN - Free Report) - Research analysts at HC Wainwright issued their FY2029 EPS estimates for OptiNose in a note issued to investors on Friday, January 3rd. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of $1.41 per share for the year. HCJanuary 6, 2025 | marketbeat.comOptinose price target adjusted for stock split at H.C. WainwrightJanuary 3, 2025 | msn.comHC Wainwright Issues Positive Forecast for OptiNose (NASDAQ:OPTN) Stock PriceHC Wainwright upped their price objective on OptiNose from $5.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday.January 3, 2025 | marketbeat.comOptiNose (NASDAQ:OPTN) Shares Down 6.1% - Time to Sell?OptiNose (NASDAQ:OPTN) Shares Down 6.1% - What's Next?January 2, 2025 | marketbeat.comOptiNose trading halted, volatility trading pauseJanuary 1, 2025 | markets.businessinsider.comOptiNose (NASDAQ:OPTN) Sees Unusually-High Trading Volume - Here's WhyOptiNose (NASDAQ:OPTN) Sees Unusually-High Trading Volume - Here's What HappenedDecember 31, 2024 | marketbeat.comOptiNose trading halted, news pendingDecember 31, 2024 | markets.businessinsider.comOptinose, Inc.: Optinose Announces 1-for-15 Reverse Stock SplitDecember 28, 2024 | finanznachrichten.deOptiNose Stock Scheduled to Reverse Split on Tuesday, December 31st (NASDAQ:OPTN)OptiNose, Inc. (NASDAQ:OPTN - Free Report) shares are scheduled to reverse split before the market opens on Tuesday, December 31st. The 1-15 reverse split was announced on Thursday, December 26th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 30th.December 27, 2024 | marketbeat.comOptinose Sets 1-for-15 Reverse Stock SplitDecember 26, 2024 | markets.businessinsider.comOptinose Announces 1-for-15 Reverse Stock SplitDecember 26, 2024 | globenewswire.com Remove Ads Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address OPTN Media Mentions By Week OPTN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPTN News Sentiment▼0.010.77▲Average Medical News Sentiment OPTN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPTN Articles This Week▼302▲OPTN Articles Average Week Remove Ads Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Allogene Therapeutics News Arcturus Therapeutics News Astria Therapeutics News Monte Rosa Therapeutics News Cryoport News Aura Biosciences News Esperion Therapeutics News Alpha Teknova News Taysha Gene Therapies News Benitec Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPTN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OPTN Stock Free OPTN Stock Alerts